06 Nov Type 2 Diabetes and Role of Bariatric Surgery
MedicalResearch.com Interview with:
Manish Parikh MD
Associate Professor of Surgery, NYU School of Medicine
Director of Bariatric Surgery, Bellevue Hospital Center
550 First Ave NBV 15 South 7
New York, NY 10010
MedicalResearch.com: What are the main findings of the study?
Dr. Parikh: The main findings of this study is that surgery is safe and effective in patients with type 2 diabetes and BMI under 35. The overall estimated rate of diabetes remission was 55% at 12 months, ranging from 33% for the adjustable gastric banding, 49% for the “mini” gastric bypass, 54% for the sleeve gastrectomy, 64% for the gastric bypass, 71% for the biliopancreatic diversion, and 81% for ileal transposition.
MedicalResearch.com: Were any of the findings unexpected?
Dr. Parikh: No, our findings mirror the existing bariatric surgery literature regarding diabetes remission in patients with BMI over 35.
MedicalResearch.com: What should clinicians and patients take away from your report?
Dr. Parikh: Although the source data are limited and outcomes reported are only short-term, bariatric surgery is very effective in patients with type 2 diabetes who do not currently meet the NIH 1991 consensus criteria for bariatric surgery.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Parikh: The estimated remission rates in this systematic review and meta-analysis can help inform future trial designs. Future studies should adopt uniform definitions of diabetes remission.
Role of bariatric surgery as treatment for type 2 diabetes in patients who do not meet current NIH criteria: a systematic review and meta-analysis.